Literature DB >> 24282721

The specialty of pulmonary vascular medicine in China: historical development and future directions.

Hua Luo1, Jingwen Li.   

Abstract

Over the past 40 years, Chinese experts have made great progress on research, diagnosis, and therapy of pulmonary vascular disease, including pulmonary embolism and pulmonary hypertension. These theoretical and clinical advances have increased public awareness about this group of conditions, which are associated with significant morbidity and mortality in China and worldwide. With its theoretical basis combining knowledge from cardiovascular and pulmonary medicine, pulmonary vascular disease has developed into a separate, unique specialty in hospitals across China and worldwide. This article will provide a short historical perspective but also an outlook into the future of this exciting novel discipline. We provide a Chinese perspective, based on our research and clinic experience over the past decades.

Entities:  

Keywords:  Specialty development; pulmonary embolism; pulmonary hypertension; pulmonary vascular disease

Year:  2012        PMID: 24282721      PMCID: PMC3839185          DOI: 10.3978/j.issn.2223-3652.2012.07.05

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  29 in total

1.  [The study of platelet function in patients with chronic pulmonary heart disease].

Authors:  Y Gao; X Weng; S Chen
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  1998-07

2.  [Physicians of the respiratory tract disease specialty should take the lead and be the example in the control of smoking].

Authors:  X Weng
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  1998-10

3.  [The current situation and strategies in management of pulmonary arterial hypertension in China].

Authors:  Zhi-Cheng Jing
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2007-09

4.  [Chronic cor pulmonale: progress in the prevention, treatment and research].

Authors:  X Cheng
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1996-11

5.  [Assessment of platelet aggregation and malondialdehyde production in patients with chronic cor pulmonale].

Authors:  Y C Zhou; X Z Weng; H G Qiu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1987-11

6.  [The therapeutic effect of defibrase on patients with an acute stage of chronic cor pulmonale].

Authors:  Y C Zhou; X Z Weng; H G Qiu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1986-07

7.  [Analysis of basic data of the study on prevention and treatment of COPD and chronic cor pulmonale].

Authors:  X Cheng; J Li; Z Zhang
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  1998-12

8.  Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension.

Authors:  Z-C Jing; X Jiang; Z-Y Han; X-Q Xu; Y Wang; Y Wu; H Lv; C-R Ma; Y-J Yang; J-L Pu
Journal:  Eur Respir J       Date:  2009-02-12       Impact factor: 16.671

9.  The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial.

Authors:  R A Raschke; B M Reilly; J R Guidry; J R Fontana; S Srinivas
Journal:  Ann Intern Med       Date:  1993-11-01       Impact factor: 25.391

10.  Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: a randomized controlled trial.

Authors:  Chen Wang; Zhenguo Zhai; Yuanhua Yang; Yadong Yuan; Zhaozhong Cheng; Lirong Liang; Huaping Dai; Kewu Huang; Weixuan Lu; Zhonghe Zhang; Xiansheng Cheng; Ying H Shen
Journal:  Respir Res       Date:  2009-12-29
View more
  2 in total

1.  Pyrroloquinoline quinone inhibits oxygen/glucose deprivation-induced apoptosis by activating the PI3K/AKT pathway in cardiomyocytes.

Authors:  Feng Xu; Haixia Yu; Jinyao Liu; Lu Cheng
Journal:  Mol Cell Biochem       Date:  2013-10-11       Impact factor: 3.396

Review 2.  Use of novel oral anticoagulant agents in venous thromboembolism.

Authors:  Shivanshu Madan; Shenil Shah; Patrick Dale; Sasan Partovi; Sahil A Parikh
Journal:  Cardiovasc Diagn Ther       Date:  2016-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.